EGFR and lung carcinoma: Additionally, ZDHHC20 palmitoylates EGFR on the C-terminal domain, leading to the activation of EGFR signaling, and knocking down ZDHHC20 has been demonstrated to reduce the growth of existing tumors derived from KRAS-mutant lung cancer cells and increase the sensitivity of these cells to EGFR inhibitors.167